Alpha 2.0
Login Register
» Articles » PMID: 35440072

Subsequent Anti-myeloma Therapy After Idecabtagene Vicleucel Treatment in Patients with Relapsed/refractory Multiple Myeloma: A Single Center Analysis

Overview
Journal Blood Cancer J
Date 2022 Apr 20
PMID 35440072
Authors
Ricardo D Parrondo
Keren Sam
Ahsan Rasheed
Victoria Alegria
Taimur Sher
Vivek Roy
Asher Chanan-Khan
Sikander Ailawadhi
Affiliations
Soon will be listed here.
Citing Articles

CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies.

Zhang X, Zhang H, Lan H, Wu J, Xiao Y Front Immunol. 2023; 14:1101495.

PMID: 36891310 PMC: 9986336. DOI: 10.3389/fimmu.2023.1101495.

Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment.

Baljevic M, Gasparetto C, Schiller G, Tuchman S, Callander N, Lentzsch S EJHaem. 2022; 3(4):1270-1276.

PMID: 36467792 PMC: 9713049. DOI: 10.1002/jha2.572.

Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy.

Van Oekelen O, Nath K, Mouhieddine T, Farzana T, Aleman A, Melnekoff D Blood. 2022; 141(7):756-765.

PMID: 36327160 PMC: 10082354. DOI: 10.1182/blood.2022017848.

Iopofosine I-131 treatment in late-line patients with relapsed/refractory multiple myeloma post anti-BCMA immunotherapy.

Longcor J, Callander N, Oliver K, Chanan-Khan A, Ailawadhi S Blood Cancer J. 2022; 12(9):130.

PMID: 36068232 PMC: 9448804. DOI: 10.1038/s41408-022-00725-2.

CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges.

Rendo M, Joseph J, Phan L, DeStefano C Blood Lymphat Cancer. 2022; 12:119-136.

PMID: 36060553 PMC: 9439649. DOI: 10.2147/BLCTT.S327016.